Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't know what your beef is with my comment. In my experience, when there is really high volume that lowers a price combined with no bad news it mean that MM's/hedge funds want in in a big way and they want shares cheap. I think that showed today. Large hedge funds picked up a lot of shares really cheap by taking advantage of weak hands and stop losses in place. They know news is imminent. Therefore, my comment on volume refers to my anticipation that this will rebound quite nicely because shares are now in stronger hands.
Trebor4: You are lyrical gangsta!!!
This is amazing stuff. I smell hedge funds. No news and ASCO acceptance goes public this coming Monday. 10 million shares by 9:30. Wow! Remember to know what you own. There is a reason why these guys want in.
Also, in my experience, big volume usually precedes big gains. Here, there is no news bringing this down.
These are the days that DD pays off. It makes you able to stomach days like this. Again, in May it all won't matter.
Great post!!!
Thanks so much for posting this. Great find. What a great interview! Discussion of partnership, trial results, etc. Good stuff.
This pattern the last couple of weeks is so similar to the movement we had between .55 and .41 a couple of months ago. Everyone was worried when it broke through resistance, etc. and it got to .41. Within 10 days, we were at .97. Stay strong longs. This stock is absolutely poised for the biggest breakout we have seen to date. Just post the picture of Punit at the NASDAQ last week and feel confident. :) By the middle of the summer no one will remember this day.
Fidelity said the same thing but made an exception both times. I'd call again and see if they will make an exception.
Loving the volume today. It's been slow go for a bit. Signs of things to come.
Couple of thoughts:
1. There is an old Chinese proverb about perspective--shit tastes like candy to a fly. I think that applies to today. We are investors not day traders. We know they are presenting at ASCO, look at this as an opportunity.
2. Get off zoridan's back. He was just frustrated and running his mouth which I do 75% of the day. I know he is long oncs and has done wonderful things for this board.
3. Zoridan's--you can buy today. I don't know which brocket age firm you use but fidelity has placed to orders for me in the last week on the same day that I didn't a money wiring. I'd call them and get it done.
Just bought 15,000 more shares. Officially have no more money to buy.
Yes. You said it better than I. I think they really have a shot. Very excited. Need to find some more money.
That's what I mean. Phase 2b fast track approval. Merkel cell and cutaneous t-cell orphans. Sorry for being unclear.
I really don't think we will make it to stage III.
Twiz, the only thing you need to worry about concerning the ASCO is your erection going lasting at least 72 hours.
To quote the great movie. " Tommy Boy " : "Hi, I'm Earth. Have we met?
Great thoughts today guys. Was golfing with my dad. Can't wait for the next few months.
It was nice reading that again. I've read that several times but has been awhile. The dots are being connected.
Best part:
Dr. Pierce comments, “We stand at a transformational moment in oncology. I’m convinced that intralesional therapy with IL12 drives systemic anti-tumor immune responses and has the potential to augment immunomodulatory therapies such as anti-PD-1.”
It's like watching teenagers try to date.
I think relatively soon. Also, the one thing that also jumped out at me was that he started ONCS when he was 27! Maybe another reason that he is smiling is that he is 30-31 years old with the option to buy 4.5 million shares of a company that might be worth $20/share. I would be wanting the "spill the beans" too. He is talking like a kid in a candy store of late.
You will love it!!!
Ya. I'm trying to figure out a way to put another 10-20k in. Gees. This is potentially a once in lifetime opportunity.
Actually, I honestly think that you will get there next year. The cool thing about the next phase 1 trials is that I expect the results will come quicker because they have largely gotten the quirks worked out with their current trials. Good stuff.
I'm getting really excited Sal with May coming up. 3 bucks and I'm a millionaire. If that doesn't get you excited, nothing will. What did you think of the video? Punit is like a kid in a candy store right now.
I know. Loved that part too!!! Big stuff coming friends!!!
He specifically stated that they are going to start multiple non-skin cancer trials!!!! Specifically, he mentioned a breast cancer. Oh boy, can't wait.
New Punit interview. Holy Cow!!! Love it.
http://t.co/kU2CYZ4dDO
We are due for an article
Song for the weekend: "Come Monday"--Jimmy buffet.
Bought 25,000 shares more.
I don't think that that data would be available to present. The press release was 3/12 with a plan to enroll. I read that as future enrollment. I'm attached the press release for convenience below. Am I wrong?
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.
The protocol addendum will allow for the assessment of the safety and efficacy of a six-week treatment cycle with ImmunoPulse in up to 21 melanoma patients. Each cycle will consist of treatments on Days 1, 8 and 15. Subjects will be eligible for an additional cycle as early as six weeks from the first treatment up to a maximum of nine treatment cycles. The protocol addendum will provide an opportunity to assess whether more frequent treatment with ImmunoPulse can provide additional clinical benefit to melanoma patients. The protocol addendum is also intended to help optimize the treatment design of the Company’s Phase IIb study in melanoma patients, which is expected to initiate in late 2014. Safety of this intensified dose regimen will also be assessed.
“ImmunoPulse is a novel intratumoral immunotherapy that has demonstrated promising efficacy for patients with advanced melanoma, while also demonstrating a favorable safety profile,” said Robert Pierce, M.D., Chief Medical Officer at OncoSec. “As we near completion of enrollment of our ongoing Phase II study—with 29 out of a total of 30 patients enrolled—we look forward to improving upon already promising results by increasing the frequency of treatments, effectively providing ‘booster shots’ for the patient’s anti-tumor immune response. To date, we have been pleased to see that approximately 60 percent of patients treated with ImmunoPulse exhibit a systemic anti-tumor immune response, evidenced by objective regression in at least one untreated lesion. By providing an enhanced immunologic ‘boost,’ we are looking to maximize patients’ anti-tumor responses.”
Adil Daud, M.D., Principal Investigator for the Phase II melanoma study, said, “Data from both studies of ImmunoPulse to date have showed encouraging results in not only the treated lesions, but in lesions that we left untreated as well. We are looking forward to enrolling the first patient in the expansion phase of this trial.”
In the current trial design, subjects are eligible to receive one treatment cycle every 12 weeks. Based on interim analysis through Day 180 of the first 21 subjects, it was shown that 38.1 percent (eight out of 21) of patients achieved an objective overall response by modified RECIST v1.1, defined as a = 30 percent reduction in the summed size of lesions. At the time of this interim analysis, six patients (28.6 percent) had demonstrated a partial response, and two patients (9.5 percent) had achieved a complete response, lasting at least six months. An additional 9.5 percent (two out of 21) of patients exhibited clinically beneficial disease stabilization for at least three months. Moreover, no treatment-related severe adverse events (SAEs) were reported and there were no adverse events (AEs) greater than grade two, and AEs were generally limited to transient pain related to electroporation treatment.
I'm thinking that this data is huge for ONCS' bargaining position. If this expansion trial data is even better, ONCS will have even more leverage in negotiating a partnership with Big Pharma. Of course, with the amount of times Punit said "partnership" yesterday, who knows.
Speaking of the expansion trial, when do you think that we would have numbers from that trial? Press release was 3/12 and the treatment is 6 weeks itself. Thoughts?
Ya. I think that is what ONCS is trying to do. See if they can increase their results with the 21 patient trial. If so and with no safety issues, then I would expect them to use that data to create a phase 2B trial using the increased dosage/frequency data and combining it with an anti-PD-1. Has real potential to bypass phase 3 altogether.
The other piece of the puzzle with timing would be the potentially increased data from ONCS' 21 patient expansion trial where it upped the frequency of treatments. That would be one heck of Phase 2B trial if the trial was based upon an already FDA approved anti-PD1 drug combined with Immunopulse (with data that is even better with increased frequency of treatments). Talk about a potential home run trial.
I've always wondered this: What is the strategy of when to release interim data throughout a trial? ONCS released interim data for the melanoma trial but we have heard nothing with the other two. I know enrollment has been the major hurdle but as many have posted today, there is data on a smaller group of patients. Why not release that now? I remember distinctly in a prior "corporate update" presentations this year, Punit repeatedly saying that FINAL data for MCC would be out in 1H of 2014. Just curious on this.
Is Bristol's comparable?
Couple of questions for the Board:
1. What was the comment from Punit about someone presenting on May 6? Was that Pierce?, what topic, and where will that be?
2. What is the timetable for MK-3475 to be approved by the FDA (rough estimate)? I thought it was 2h 2014? No?
3. Is there another Big Pharma that has trial results that are anywhere close to MK-3475?
4. Now that we know that ASCO will be melanoma, what do you think the difference will be at ASGOT?
The song that is most applicable to today's new is:
Tag Team, "Whoomp there it is"